Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

  1. Rugo, H.S.
  2. André, F.
  3. Yamashita, T.
  4. Cerda, H.
  5. Toledano, I.
  6. Stemmer, S.M.
  7. Jurado, J.C.
  8. Juric, D.
  9. Mayer, I.
  10. Ciruelos, E.M.
  11. Iwata, H.
  12. Conte, P.
  13. Campone, M.
  14. Wilke, C.
  15. Mills, D.
  16. Lteif, A.
  17. Miller, M.
  18. Gaudenzi, F.
  19. Loibl, S.
Aldizkaria:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Argitalpen urtea: 2020

Alea: 31

Zenbakia: 8

Orrialdeak: 1001-1010

Mota: Artikulua

DOI: 10.1016/J.ANNONC.2020.05.001 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus